Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1980 1
1981 3
1982 5
1983 5
1984 3
1985 1
1986 7
1987 5
1988 8
1989 4
1990 6
1991 4
1992 4
1993 9
1994 12
1995 11
1996 16
1997 16
1998 11
1999 12
2000 14
2001 14
2002 6
2003 5
2004 7
2005 8
2006 11
2007 7
2008 6
2009 7
2010 4
2011 8
2012 4
2013 10
2014 5
2015 9
2016 4
2017 7
2018 3
2019 5
2020 3
2021 4
2022 6
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

295 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM, Jiang XT, Chen CC, Luo JC, Bair MJ, Chen PY, Chou CK, Fang YJ, Chen MJ, Chen CC, Lee JY, Yang TH, Yu CC, Kuo CC, Chiu MC, Chen CY, Shun CT, Hu WH, Tsai MH, Hsu YC, Tseng CH, Chang CY, Lin JT, El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Liou JM, et al. Lancet Gastroenterol Hepatol. 2023 Mar;8(3):228-241. doi: 10.1016/S2468-1253(22)00384-3. Epub 2022 Dec 19. Lancet Gastroenterol Hepatol. 2023. PMID: 36549320 Clinical Trial.
Adult patients (age 20 years) with persistent H pylori infection after first-line clarithromycin-based therapy were randomly assigned (1:1, permuted block sizes of four) to receive levofloxacin-based sequential quadruple therapy for 14 days (EAML14; esomeprazole 40 mg and amoxici …
Adult patients (age 20 years) with persistent H pylori infection after first-line clarithromycin-based therapy were randomly assigned (1:1, …
Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
Park KN, Hahm JS, Kim HJ. Park KN, et al. Eur J Gastroenterol Hepatol. 1994 Dec;6 Suppl 1:S103-7. Eur J Gastroenterol Hepatol. 1994. PMID: 7735924 Clinical Trial.
PURPOSE: Two 4-week triple-therapy treatment regimens, metronidazole+tetracycline+bismuth subcitrate and omeprazole+amoxycillin+bismuth subcitrate, were compared in a randomly allocated double-blind trial for their efficacy in eradicating Helicobacter …
PURPOSE: Two 4-week triple-therapy treatment regimens, metronidazole+tetracycline+bismuth subcitrate and omeprazole+amoxycilli …
Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection.
Bang CS, Lim H, Jeong HM, Shin WG, Choi JH, Soh JS, Kang HS, Yang YJ, Hong JT, Shin SP, Suk KT, Lee JJ, Baik GH, Kim DJ. Bang CS, et al. Gut Microbes. 2020 Sep 2;11(5):1314-1323. doi: 10.1080/19490976.2020.1754118. Epub 2020 May 2. Gut Microbes. 2020. PMID: 32362221 Free PMC article. Clinical Trial.
Subjects endoscopically diagnosed with H. pylori infection were randomly allocated to receive modified quadruple- (rabeprazole 20 mg bid, amoxicillin 1 g bid, metronidazole 500 mg tid, bismuth subcitrate 300 mg qid [elemental bismuth 480 mg]; PAMB) or bismuth-contai …
Subjects endoscopically diagnosed with H. pylori infection were randomly allocated to receive modified quadruple- (rabeprazole 20 mg bid, am …
Double-blind comparison of absorbable colloidal bismuth subcitrate and nonabsorbable bismuth subnitrate in the eradication of Helicobacter pylori and the relief of nonulcer dyspepsia.
Whitehead MW, Phillips RH, Sieniawska CE, Delves HT, Seed PT, Thompson RP, Powell JJ. Whitehead MW, et al. Helicobacter. 2000 Sep;5(3):169-75. doi: 10.1046/j.1523-5378.2000.00027.x. Helicobacter. 2000. PMID: 10971683 Clinical Trial.
Whether bismuth has to be absorbed in humans to act against H. pylori is not known. In this study, we compared "absorbable" (colloidal bismuth subcitrate) and "nonabsorbable" (bismuth subnitrate) bismuth as part of triple therapy in the eradication of H. pylori. MAT …
Whether bismuth has to be absorbed in humans to act against H. pylori is not known. In this study, we compared "absorbable" (colloidal bi …
Colloidal bismuth pectin: an alternative to bismuth subcitrate for the treatment of Helicobacter pylori--positive duodenal ulcer.
Nie Y, Li Y, Wu H, Sha W, Du H, Dai S, Wang H, Li Q. Nie Y, et al. Helicobacter. 1999 Jun;4(2):128-34. doi: 10.1046/j.1523-5378.1999.98281.x. Helicobacter. 1999. PMID: 10382127 Clinical Trial.
MATERIALS AND METHODS: In this prospective trial, 205 patients with H. pylori-positive duodenal ulcer were allocated randomly to receive one of four regimens: metronidazole, 200 mg; amoxicillin, 250 mg; and colloidal bismuth subcitrate (CBS), 120 mg (group 1), or CB …
MATERIALS AND METHODS: In this prospective trial, 205 patients with H. pylori-positive duodenal ulcer were allocated randomly to receive one …
Bismuth-based triple therapy with bismuth subcitrate, metronidazole and tetracycline in the eradication of Helicobacter pylori: a randomized, placebo controlled, double-blind study.
Veldhuyzen Van Zanten S, Farley A, Marcon N, Lahaie R, Archambault A, Hunt R, Bailey R, Owen D, Spénard J, Stiglick A, Aimola N, Colin P. Veldhuyzen Van Zanten S, et al. Can J Gastroenterol. 2000 Jul-Aug;14(7):599-602. doi: 10.1155/2000/690307. Can J Gastroenterol. 2000. PMID: 10978947 Clinical Trial.
OBJECTIVE: To determine the rate of Helicobacter pylori eradication following bismuth-based triple therapy with colloidal bismuth subcitrate, tetracycline hydrochloride and metronidazole. PATIENTS AND METHODS: One hundred and eleven patients were randomly assigned, …
OBJECTIVE: To determine the rate of Helicobacter pylori eradication following bismuth-based triple therapy with colloidal bismuth …
Effect of colloidal bismuth subcitrate on symptoms and gastric histology in non-ulcer dyspepsia. A double blind placebo controlled study.
Kang JY, Tay HH, Wee A, Guan R, Math MV, Yap I. Kang JY, et al. Gut. 1990 Apr;31(4):476-80. doi: 10.1136/gut.31.4.476. Gut. 1990. PMID: 2186982 Free PMC article. Clinical Trial.
The aim of this study was to determine the effect of colloidal bismuth subcitrate (De Nol) on symptoms and gastric histology in patients with non-ulcer dyspepsia. ...In contrast, patients who did not have gastritis in their index biopsies (n = 28) fared similarly wh …
The aim of this study was to determine the effect of colloidal bismuth subcitrate (De Nol) on symptoms and gastric histology i …
Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study.
Peng X, Chen HW, Wan Y, Su PZ, Yu J, Liu JJ, Lu Y, Zhang M, Yao JY, Zhi M. Peng X, et al. Clin Exp Med. 2023 Nov;23(7):4011-4019. doi: 10.1007/s10238-023-01074-5. Epub 2023 Apr 28. Clin Exp Med. 2023. PMID: 37115412 Clinical Trial.
They were randomly assigned into the VA-dual group (vonoprazan 20 mg b.i.d + amoxicillin 750 mg q.i.d) or EACP-quadruple group (esomeprazole 20 mg + amoxicillin 1000 mg + clarithromycin 500 mg + colloidal bismuth subcitrate 220 mg b.i.d) for 14 days in a ratio of 1: …
They were randomly assigned into the VA-dual group (vonoprazan 20 mg b.i.d + amoxicillin 750 mg q.i.d) or EACP-quadruple group (esomeprazole …
Bismuth salts with versus without acid suppression for Helicobacter pylori infection: A transmission electron microscope study.
Chiang TH, Chen CC, Tseng PH, Liou JM, Wu MS, Shun CT, Lee YC, Graham DY. Chiang TH, et al. Helicobacter. 2021 Jun;26(3):e12801. doi: 10.1111/hel.12801. Epub 2021 Mar 19. Helicobacter. 2021. PMID: 33740276 Clinical Trial.
The effect of bismuth salts on H. pylori in the presence of strong acid suppression is unknown. This randomized trial aimed to determine effects of bismuth subcitrate on H. pylori with and without acid suppression. METHODS: H. pylori -positive participants were allo …
The effect of bismuth salts on H. pylori in the presence of strong acid suppression is unknown. This randomized trial aimed to determine eff …
295 results

Searches related to "bismuth subcitrate"